Clinical effectiveness of the medicine Allergoferon in the treatment of intermittent rhinoconjunctivitis in patients of different age groups


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective: to assess the clinical effectiveness of the combined medicine Allergoferon (recombinant interferon alpha-2b + loratadine) in the form of gel for the treatment of allergic rhinoconjunctivitis in young and middle-aged adult patients. Materials and methods. The study included 56 patients with allergic rhinoconjunctivitis. They were divided into two groups according to their age: group 1 - 22-45 years and group 2 - 45-60 years. All patients received the combined medicine Allergoferon for the treatment of allergic rhinoconjunctivitis. The gel was applied to the skin of the upper and lower eyelids and to the nasal mucous membranes four times a day. Analysis of the treatment effectiveness was based on the assessment of the positive symptom dynamics. The symptoms were scored on a 4-point scale: 1 - not expressed; 2 - mild; 3 - moderate; 4 - severe. Results. During topical treatment with the medicine Allergoferon the severity of all evaluated symptoms was statistically significantly reduced: in 41-64% of patients already on the 7th treatment day (p<0,05), whereas on the 14th day symptoms were resolved in 86% of patients. Patients aged under 45 years (group 1) had more severe symptoms at baseline, than older patients (group 2). A complete resolution of clinical symptoms during topical treatment with the medicine Allergoferon was achieved faster (by 2.8±0.5 days) in the first group patients compared to the second group patients. Conclusion. The use of the combined medicine Allergoferon in the treatment of intermittent rhinoconjunctivitis was characterised by the symptom reduction during the first days of treatment; a complete relief of symptoms was observed in 86% of patients by the end of the second treatment week. Despite more severe clinical symptoms in younger patients at baseline, therapeutic effect of this medicine was achieved on average 2.8±0.5 days faster in younger patients, than in older patients (p<0.05). According to the correlation analysis, early use of the given medicine was associated with a more rapid reduction in disease symptoms and improved quality of life - r=0.54 (p<0.05).

全文:

受限制的访问

作者简介

A. Shavrin

Perm State Medical University named after E.A. Wagner

Email: ashavrin1@mail.ru

参考

  1. Курбачева О.М., Павлова К.С. Поллиноз: диагностика, клиника, лечение. Медицинская кафедра. 2003; 2 (6): 38-45 @@Kurbacheva O.M., Pavlova K.S. Pollinoz: diagnostika, klinika, lechenie. Meditsinskaya kafedra. 2003; 2 (6): 38-45 (in Russ.)
  2. Аллергический риноконъюнктивит: клинические рекомендации. Под ред. А.С. Лопатина. М.: Практическая медицина, 2015; 96 с. @@Allergicheskii rinokon»yunktivit: klinicheskie rekomendatsii. Pod red. A.S. Lopatina. M.: Prakticheskaya meditsina, 2015; 96 s. (in Russ.)
  3. Аллергология. Федеральные клинические рекомендации. Под ред. Р.М. Хаитова, Н.И. Ильиной. М.: Фармарус Принт Медиа, 2014; 126 с. @@Allergologiya. Federal’nye klinicheskie rekomendatsii. Pod red. R.M. Khaitova, N.I. Il’inoi. M.: Farmarus Print Media, 2014; 126 s. (in Russ.)
  4. Горячкина Л.А., Передкова Е.В., Храмцова Н.Н. Поллинозы: Учеб. пособие. М.: ООО «Колор Ит Студио», 2004; 24 с. @@Goryachkina L.A., Peredkova E.V., Khramtsova N.N. Pollinozy: Ucheb. posobie. M.: OOO «Kolor It Studio», 2004; 24 s. (in Russ.)
  5. Зайцева С.В., Локшина Э.Э., Муртазаева О.А. и др. Современные возможности терапии поллиноза у детей. РМЖ. 2012; 6: 314 @@Zaitseva S.V., Lokshina E.E., Murtazaeva O.A. et al. Sovremennye vozmozhnosti terapii pollinoza u detei. RMJ. 2012; 6: 314 (in Russ.)]. URL: https://www.rmj.ru/articles/bolezni_dykhatelnykh_putey/ Sovremennye_vozmoghnosti_terapii_pollinoza_u_detey/
  6. Данилычева И.В. Некоторые аспекты образа жизни больных поллинозом. Consilium medicum. 2003; 5 (4): 223-5 @@ Danilycheva I.V. Nekotorye aspekty obraza zhizni bol’nykh pollinozom. Consilium medicum. 2003; 5 (4): 223-5 (in Russ.)
  7. Pritchard A.L., White O.J., Burel J.G. et al. Innate interferons inhibit allergen and microbial specific Th2 responses. Immunol Cell Biol. 2012; 90 (10): 974-7. doi: 10.1038/icb.2012.39
  8. Gonzalesvan Horn S.R., Farrar J.D. Interferon at the crossroads of allergy and viral infections. J Leukoc Biol. 2015; 98 (2): 185-94. doi: 10.1189/jlb.3RU0315-099R. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501675/
  9. Huber J.P., Gonzalesvan Horn S.R., Roybal K.T. et al. IFN- Suppresses GATA3 Transcription from a Distal Exon and Promotes H3K27 Trimethylation of the CNS-1 Enhancer in Human Th2 Cells. J Immunol. 2014; 192 (12): 5687. DOI: 10.4049/ jimmunol.1301908
  10. Гапонюк П.Я. Новый подход к лечению больных с аллергическим ринитом. Аллергология и иммунология. 2008; 9: 277 @@Gaponyuk P.Ya. New approach to the treatment of patients with allergic rhinitis. Allergology and Immunology. 2008; 9: 277 (in Russ.)
  11. Сотникова Н.Ю. Новые возможности в лечении аллергического ринита и аллергического конъюнктивита: топические препараты. Инфекционные болезни: новости, мнения, обучение. 2017; 1: 42-50 @@Sotnikova N.Yu. New perspectives in the treatment of allergic rhinitis and conjunctivitis: topical medications. Infektsionnye bolezni: novosti, mneniya, obuchenie. 2017; 1: 42-50 (in Russ.).
  12. Трухан Д.И., Лебедев О.И. Изменение органа зрения при соматических заболеваниях. Тер арх. 2015; 87 (8): 132-6 @@Trukhan D.I., Lebedev O.I. Change in the organ of vision in somatic diseases. Therapeutic Archive. 2015; 87 (8): 132-6 (in Russ.). doi: 10.17116/terarkh2015878132-136
  13. Трухан Д.И., Алексеенко В.А., Калашникова Н.М. и др. Опыт применения комбинированных препаратов рекомбинантного интерферона альфам в лечении аллергических ринитов. Врач. 2021; 32 (3): 73-81 @@Trukhan D., Alekseenko V., Kalashnikova N. et al. The use of combined recombinant interferon alpha-2b medications in the treatment of allergic rhinitis. Vrach. 2021; 32 (3): 73-81 (in Russ.). doi: 10.29296/25877305-2021-03-13
  14. Сотникова Н.Ю., Пахомава Т.В., Лыкова Т.А. Лечебная эффективность комбинированного препарата Аллергоферон® при персистирующем аллергическом рините. Российский аллергологический журнал. 2016; 1: 52-6 @@Sotnikova N.Y., Pachomova T.V., Lykova T.A. Treatment efficacy of the combined medication Allergoferon® during persistent allergic rhinitis. Rossiiskii allergologicheskii zhurnal. 2016; 1: 52-6 (in Russ.).
  15. Суров А.В., Заспина А.Г. Опыт применения лекарственного препарата интерферон альфам в сочетании с лоратадином в виде геля для местного и наружного применения в комплексной терапии аллергических заболеваний глаз. Офтальмология. 2014; 11 (1): 63-5 @@Surov A.V., Zaspina A.G. Complex treatment of allergic eye diseases using interferon alpha-2b and loratadine gel for topical and external use. Ophthalmology in Russia. 2014; 11 (1): 62-5 (in Russ.)]. doi: 10.18008/1816-5095-2014-1-62-65
  16. Нестерова К.И., Нестерова А.А. Эффективность топической антигистаминной монотерапии при манифестации сезонного аллергического ринита. Вестник оториноларингологии. 2015; 80 (4): 77-80 @@Nesterova K.I., Nesterova A.A. The effectiveness of topical antihistamine monotherapy in the patients presenting with the manifestations of seasonal allergic rhinitis. Bulletin of Otorhinolaryngology. 2015; 80 (4): 77-80 (in Russ.)]. doi: 10.17116/otorino201580477-80

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Russkiy Vrach Publishing House, 2021
##common.cookie##